{"id":10726,"date":"2022-12-09T11:47:26","date_gmt":"2022-12-09T11:47:26","guid":{"rendered":"https:\/\/ultimatehealthreport.com\/is-self-regulation-essential-to-effective-legislation\/"},"modified":"2022-12-09T11:47:26","modified_gmt":"2022-12-09T11:47:26","slug":"is-self-regulation-essential-to-effective-legislation","status":"publish","type":"post","link":"https:\/\/ultimatehealthreport.com\/is-self-regulation-essential-to-effective-legislation\/","title":{"rendered":"Is Self-Regulation Essential to Effective Legislation?"},"content":{"rendered":"
\n<\/p>\n
The cannabis industry is characterized by regulatory uncertainty and volatility. State-by-state variation, frequent updates to the rules of the road, and an ongoing \u201cwill they or won\u2019t they\u201d federal stance have made it clear that this is not an industry for the risk-averse or the timid.<\/p>\n
Add to that a relative newcomer on the scene, delta-8 THC. Over the past two years, federal courts have wrestled with the legal status of hemp-derived THC products. <\/p>\n
The legalization of hemp derivatives and extracts in the 2018 Farm Bill, combined with the capacity to derive delta-8 THC in psychoactively potent amounts, has created a gray zone. <\/p>\n
Companies are allowed to manufacture and sell products that mimic the effect of a cannabis high without all the legal and regulatory hurdles that accompany cannabis.<\/p>\n
How you feel about this depends on where you sit. If you\u2019re in the hemp or CBD space, it\u2019s a good thing. You have a legal product to sell that is attractive to consumers. <\/p>\n
If you\u2019re in the regulated cannabis space, this is a problem. <\/p>\n
You have incurred immense costs navigating a highly regulated industry and you\u2019re watching competitors zip by you, grabbing market share with a fraction of the headaches.<\/p>\n
There\u2019s a large, common problem on the horizon, however: state regulatory policy. To understand it requires taking off the industry hat and putting on the regulator\u2019s hat. <\/p>\n
Most industry analyses are written from the perspective of the businesses and the investors. How does this rule affect the bottom line? What\u2019s the impact on attractiveness to investors? <\/p>\n
How do we adjust the business plan to the current environment?<\/p>\n
Effective planning calls for thinking like regulators and considering the problems they are solving. <\/p>\n
What\u2019s the regulatory capacity to oversee the CBD space? Are we funded for it? Do we have the staff to do it well? Are the political players who matter (as opposed to opinion polls) pro-cannabis or anti-cannabis? <\/p>\n
Regulators\u2019 analysis of those questions will shape the policies that impact your business. \u00a0<\/p>\n